Combined Photodynamic Therapy and Intravitreal Triamcinolone Acetonide for the Treatment of Myopic Subfoveal Choroidal Neovascularization

Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome

“…Anti-angiogenic therapies, such as intravitreous triamcinolone,9 10 21 22 intravitreous bevacizumab11 – 18 and intravitreous ranibizumab, have been used to treat subfoveal myopic CNV 23…”

Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years?

“…Another therapeutic approach was a combined therapy with verteporfin PDT and intravitreal or subtenonal administration of triamcinolone [4]. Marticorena et al reported promising results after 7 days, and 1 and 3 months of combined therapy [5]. However, Chan et al found no significant difference between PDT alone and in combination with intravitreal triamcinolone after 12 months of follow-up [6].…”

Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses

“…Different therapeutic approaches have been tried for myopic CNV, including argon laser photocoagulation [2,3], surgery [4,5], and photodynamic therapy with verteporfin (PDT) alone [6][7][8], or associated with intravitreal triamcinolone acetonide injection [9][10][11].…”